In Reply to Letter to Editor Regarding "A Multicenter, Randomized, Double-Blind, Imipenem/cilastatin-Controlled Clinical Study of Cefiderocol for the Treatment of Complicated Urinary Tract Infections Caused by Gram-negative Pathogens in Chinese Adults".